Papers - KAIKITA Koichi
-
East Asian variant aldehyde dehydrogenase type 2 genotype exacerbates ischemia/reperfusion injury with ST-elevation myocardial infarction in men: possible sex differences. Reviewed
Ishida T, Arima Y, Mizuno Y, Harada E, Yamashita T, Sueta D, Sakamoto K, Suzuki S, Kaikita K, Yamada Y, Shimomura H, Oniki K, Saruwatari J, Hokimoto S, Yasue H, Tsujita K
Heart and vessels 37 ( 2 ) 184 - 193 2021.7
Language：English Publishing type：Research paper (scientific journal)
-
Kumamoto Intervention Conference Study (KICS) Investigators. Imaging‑guided PCI for event suppression in Japanese acute coronary syndrome patients: community‑based observational cohort registry Reviewed
Yamashita T, Sakamoto K, Tabata N, Ishii M, Sato R, Nagamatsu S, Motozato K, Yamanaga K, Sueta D, Araki S, Arima Y, Yamamoto E, Takashio S, Fujisue K, Fujimoto K, Shimomura H, Tsunoda R, Maruyama H, Nakamura N, Sakaino N, Nakamura S, Yamamoto N, Matsumura T, Kajiwara I, Tayama S, Sakamoto T, Nakao K, Oshima S, Kaikita K, Hokimoto S, Tsujita K
Cardiovascular Intervention and Therapeutics 36 ( 1 ) 81 - 90 2021.7
Language：English Publishing type：Research paper (scientific journal)
-
Akao M., Yasuda S., Kaikita K., Ako J., Matoba T., Nakamura M., Miyauchi K., Hagiwara N., Kimura K., Hirayama A., Matsui K., Ogawa H.
American Heart Journal 236 59 - 68 2021.6
Language：English Publishing type：Research paper (scientific journal) Publisher：American Heart Journal
Background: In the AFIRE trial, rivaroxaban monotherapy was noninferior to combination therapy with rivaroxaban and an antiplatelet agent for thromboembolic events or death, and superior for major bleeding in patients with atrial fibrillation (AF) and stable coronary artery disease. Little is known about impacts of stroke and bleeding risks on the efficacy and safety of rivaroxaban monotherapy. Methods: In this subanalysis of the AFIRE trial, we assessed the risk of stroke and bleeding by the CHADS2, CHA2DS2-VASc, and HAS-BLED scores. The primary efficacy end point was the composite of stroke, systemic embolism, myocardial infarction (MI), unstable angina requiring revascularization, or death from any cause. The primary safety end point was major bleeding defined by the International Society on Thrombosis and Haemostasis. Results: Rivaroxaban monotherapy significantly reduced the primary efficacy and safety end points with no evidence of differential effects by stroke risk (CHADS2, p for interaction = 0.727 for efficacy, 0.395 for safety; CHA2DS2-VASc, p for interaction = 0.740 for efficacy, 0.265 for safety) or bleeding risk (HAS-BLED, p for interaction = 0.581 for efficacy, 0.225 for safety). There was also no evidence of statistical heterogeneity across patient risk categories for other end points; stroke or systemic embolism, ischemic stroke, hemorrhagic stroke, MI, MI or unstable angina, death from any cause, any bleeding, or net adverse clinical events. Conclusions: The advantages of rivaroxaban monotherapy compared with those of combination therapy with respect to all prespecified end points, including thromboembolism, bleeding, and mortality were similar across patients with AF and stable coronary artery disease, irrespective of their risk for stroke and bleeding. Clinical Trial Registration: UMIN Clinical Trials Registry number, UMIN000016612, and ClinicalTrials.gov number, NCT02642419.
-
Egashira K., Sueta D., Tomiguchi M., Kidoh M., Oda S., Usuku H., Hidaka K., Goto-Yamaguchi L., Sueta A., Komorita T., Takae M., Oike F., Fujisue K., Yamamoto E., Hanatani S., Takashio S., Arima Y., Araki S., Kaikita K., Matsushita K., Yamamoto Y., Hirai T., Tsujita K.
IJC Heart and Vasculature 34 100797 2021.6
Language：English Publishing type：Research paper (scientific journal) Publisher：IJC Heart and Vasculature
Cardiotoxicity in the late phase after anthracycline drugs administration remains to be defined. Of the 44 patients who received anthracycline treatment, 7 were found to have cancer therapeutics–related cardiac dysfunction (CTRCD). The global longitudinal strain determined by echocardiography and myocardial extracellular volume fraction (ECV) determined by cardiac computed tomography (CCT) of the CTRCD(+) group were significantly higher than those of the control group and CTRCD(-) group, whereas there were no significant differences between the control and CTRCD(-) groups. Our findings indicated that CCT may be a tool comparable to echocardiography, indicating the effective evaluation of CTRCD by CCT.
-
A Coronary Artery-Left Ventricular Fistula Through the Sinusoid. Reviewed
Sato K, Misumi I, Nagano M, Arima R, Ehara S, Sakamoto T, Usuku H, Kaikita K, Tsujita K
Internal medicine (Tokyo, Japan) 60 ( 23 ) 3755 - 3758 2021.5
Language：English Publishing type：Research paper (scientific journal) Publisher：一般社団法人 日本内科学会
A 78-year-old woman was referred to our hospital because of repetitive suppurative arthritis at the artificial left knee joint. Her plasma brain natriuretic peptide level was 122 pg/mL. A 12-lead electrocardiogram showed a QS pattern in the inferior leads. A two-dimensional echocardiogram revealed hypokinesis at the inferior wall and hypertrophy at the apical lateral wall. Color flow imaging revealed this hypertrophic region to be a myocardial sinusoid, demonstrating diastolic coronary to left ventricular flow and early systolic flow vice versa. This was a very rare case of coronary to left ventricular fistula through a sinusoid without cyanotic congenital heart disease or severe coronary artery disease.
-
Emoto T., Oda S., Kidoh M., Nakaura T., Nagayama Y., Sakabe D., Kakei K., Goto M., Funama Y., Hatemura M., Takashio S., Kaikita K., Tsujita K., Ikeda O.
Academic Radiology 28 ( 5 ) e119 - e126 2021.5
Language：English Publishing type：Research paper (scientific journal) Publisher：Academic Radiology
Rationale and Objectives: To clarify the accuracy of two measurement methods for myocardial extracellular volume (ECV) quantification (ie, the standard subtraction method [ECV ] and the dual-energy iodine method [ECV ]) with the use of cardiac CT in comparison to cardiac magnetic resonance imaging (CMR) as a reference standard. Materials and Methods: Equilibrium phase cardiac images of 21 patients were acquired with a dual-layer spectral detector CT and CMR, and the images were retrospectively analyzed. CT-ECV was calculated using ECV and ECV . The correlation between the ECV values measured by each method was assessed. Bland-Altman analysis was used to identify systematic errors and to determine the limits of agreement between the CT-ECV and CMR-ECV values. Root mean squared errors and residual values for the ECV and ECV were also assessed. Results: The correlations between ECV and ECV for both septal and global measurement were r = 0.95 (p < 0.01) and 0.91 (p < 0.01), respectively, while those between the mean ECV and CMR-ECV were r = 0.90 (septal, p < 0.01) and 0.84 (global, p < 0.01), and those between ECV and CMR-ECV were r = 0.94 (septal, p < 0.01) and 0.95 (global, p < 0.01). Bland-Altman plots showed lower 95% limits of agreement between ECV and CMR-ECV compared with that between ECV and CMR-ECV in both septal and global measurement. The root mean squared error of ECV was higher than that of ECV . The mean residual value of ECV was significantly higher than that of ECV . Conclusion: ECV yielded more accurate myocardial ECV quantification than ECV , and provided a comparable ECV value to that obtained by CMR. sub iodine sub iodine sub iodine sub iodine sub iodine iodine sub sub iodine sub iodine iodine sub
-
Significance of Blood Test During Antithrombotic Therapy Reviewed
45 ( 5 ) 273 - 279 2021.5
Authorship：Lead author Language：Japanese Publishing type：Research paper (scientific journal)
-
抗血栓療法時の検査法の意義.
海北幸一, 辻田賢一.
ICUとCCU 集中治療医学 45 ( 5 ) 273 - 279 2021.5
Authorship：Lead author Publishing type：Research paper (scientific journal)
-
JCS 2018 Guideline on Diagnosis of Chronic Coronary Heart Diseases. Reviewed
Yamagishi M, Tamaki N, Akasaka T, Ikeda T, Ueshima K, Uemura S, Otsuji Y, Kihara Y, Kimura K, Kimura T, Kusama Y, Kumita S, Sakuma H, Jinzaki M, Daida H, Takeishi Y, Tada H, Chikamori T, Tsujita K, Teraoka K, Nakajima K, Nakata T, Nakatani S, Nogami A, Node K, Nohara A, Hirayama A, Funabashi N, Miura M, Mochizuki T, Yokoi H, Yoshioka K, Watanabe M, Asanuma T, Ishikawa Y, Ohara T, Kaikita K, Kasai T, Kato E, Kamiyama H, Kawashiri M, Kiso K, Kitagawa K, Kido T, Kinoshita T, Kiriyama T, Kume T, Kurata A, Kurisu S, Kosuge M, Kodani E, Sato A, Shiono Y, Shiomi H, Taki J, Takeuchi M, Tanaka A, Tanaka N, Tanaka R, Nakahashi T, Nakahara T, Nomura A, Hashimoto A, Hayashi K, Higashi M, Hiro T, Fukamachi D, Matsuo H, Matsumoto N, Miyauchi K, Miyagawa M, Yamada Y, Yoshinaga K, Wada H, Watanabe T, Ozaki Y, Kohsaka S, Shimizu W, Yasuda S, Yoshino H, Japanese Circulation Society Working Group.
Circulation journal : official journal of the Japanese Circulation Society 85 ( 4 ) 402 - 572 2021.3
Language：English Publishing type：Research paper (scientific journal)
-
Nakanishi N., Kaikita K., Ishii M., Kuyama N., Tabata N., Ito M., Yamanaga K., Fujisue K., Hoshiyama T., Kanazawa H., Hanatani S., Sueta D., Takashio S., Arima Y., Araki S., Usuku H., Nakamura T., Suzuki S., Yamamoto E., Soejima H., Matsushita K., Tsujita K.
International Journal of Cardiology 325 121 - 126 2021.2
Authorship：Corresponding author Language：English Publishing type：Research paper (scientific journal) Publisher：International Journal of Cardiology
Background: Antithrombotic therapy is established for the treatment of various cardiovascular events. However, it has been shown to increase the bleeding risk. Total Thrombus-formation Analysis System (T-TAS) is reported to be useful for evaluating thrombogenicity. Here, we estimated whether T-TAS is useful for predicting bleeding events risk in patients undergoing percutaneous coronary intervention (PCI). Methods: This was a retrospective, observational study at Kumamoto University Hospital between April 2017 and March 2019. Blood samples obtained on the day of PCI were used in T-TAS to compute the thrombus formation area under the curve (AUC) (AR -AUC , AUC for AR chip). We divided the study population into 2 groups according to the Academic Research Consortium for High Bleeding Risk (ARC-HBR) (182 patients in ARC-HBR positive, 118 in ARC-HBR negative). The primary endpoint was 1-year bleeding events that were defined by Bleeding Academic Research Consortium type2, 3, or 5. Results: The AR -AUC levels were significantly lower in the ARC-HBR positive group than in the ARC-HBR negative group (median [interquartile range] 1571.4 [1277.0–1745.3] vs. 1726.2 [1567.7–1799.6], p < 0.001). The combination of ARC-HBR and AR -AUC could discriminate the bleeding risk, and improved predictive capacity compared with ARC-HBR by c-statistics. Decision-curve analysis also revealed that combining AR -AUC with ARC-HBR ameliorated bleeding risk-prediction. In multivariate Cox hazards analyses, combining ARC-HBR with lower AR -AUC levels was significantly associated with 1-year bleeding events. Conclusions: The results highlight that AR -AUC evaluated by T-TAS could be a potentially useful marker for predicting high bleeding risk in patients undergoing PCI. 10 30 10 30 10 30 10 30 10 30 10 30
-
Fujisue K., Yamanaga K., Nagamatsu S., Shimomura H., Yamashita T., Nakao K., Nakamura S., Ishihara M., Matsui K., Sakaino N., Miyazaki T., Yamamoto N., Koide S., Matsumura T., Fujimoto K., Tsunoda R., Morikami Y., Matsuyama K., Oshima S., Sakamoto K., Izumiya Y., Kaikita K., Hokimoto S., Ogawa H., Tsujita K.
Journal of Atherosclerosis and Thrombosis 28 ( 2 ) 181 - 193 2021.2
Language：English Publishing type：Research paper (scientific journal) Publisher：Journal of Atherosclerosis and Thrombosis
Aim: Coronary plaque regression is weak in acute coronary syndrome (ACS) patients with diabetes mellitus (DM). We evaluated whether dual lipid-lowering therapy (DLLT) with ezetimibe and atorvastatin attenuates coronary plaques in ACS patients with DM. Methods: The prospective, randomized controlled, multicenter PRECISE-IVUS (Plaque Regression with Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by Intravascular Ultrasound) trial assigned 246 patients undergoing percutaneous coronary intervention to DLLT or atorvastatin monotherapy and evaluated IVUS-derived changes in percent atheroma volume (ΔPAV), at baseline and 9–12-month follow-up, in 126 ACS cases, including 25 DM patients. The atorvastatin dose was up-titrated to achieve low-density lipoprotein cholesterol (LDL-C) ＜70 mg/dL. Results: In DM patients, the monotherapy group (n=13) and the DLLT group (n=12) showed a similar preva-lence of coronary risks and baseline lipid profiles. During the study, the change in LDL-C level was similar between DM and non-DM patients. Compared with non-DM patients, DM patients showed weaker regression of ΔPAV by DLLT than those who underwent monotherapy (DM: −2.77±3.47% vs. −0.77±2.51%, P=0.11; non-DM: −2.01±3.36% vs. −0.08±2.66%, P=0.008). The change in LDL-C level was not correlated with Δ PAV in non-DM patients, but there was significant correlation between the change in LDL-C level and ΔPAV in DM patients (r=0.52, P=0.008). Conclusions: ACS patients with DM showed weaker coronary plaque regression than their counterparts. A significant correlation between the change in LDL-C level and ΔPAV in DM patients suggested that more intensive lipid-lowering therapy is required in ACS patients with DM.
DOI： 10.5551/jat.54726
-
Temporal trends in coronary intervention strategies and the impact on one-year clinical events: data from a Japanese multi-center real-world cohort study. Reviewed
Sakamoto K, Sato R, Tabata N, Ishii M, Yamashita T, Nagamatsu S, Motozato K, Yamanaga K, Hokimoto S, Sueta D, Araki S, Fujisue K, Arima Y, Takashio S, Fujimoto K, Shimomura H, Tsunoda R, Hirose T, Sato K, Kikuta K, Sakaino N, Nakamura S, Yamamoto N, Matsumura T, Kajiwara I, Tayama S, Sakamoto T, Nakao K, Oshima S, Yamamoto E, Kaikita K, Tsujita K, Kumamoto Intervention Conference Study (KICS) Investigators.
Cardiovascular intervention and therapeutics 37 ( 1 ) 66 - 77 2021.1
Language：English Publishing type：Research paper (scientific journal)
-
特集 抗血小板･抗凝固薬投与の問題は解決した? 診る4 抗血栓療法の効果はどこまで評価できるか?
海北幸一, 辻田賢一.
Heart View 25 ( 1 ) 26 - 31 2021.1
Authorship：Lead author Publishing type：Research paper (scientific journal)
-
Nishihara T., Tokitsu T., Sueta D., Oike F., Takae M., Fujisue K., Usuku H., Ito M., Kanazawa H., Araki S., Arima Y., Takashio S., Nakamura T., Sakamoto K., Suzuki S., Kaikita K., Yamamoto E., Tsujita K.
Journal of Cardiac Failure 27 ( 1 ) 57 - 66 2021.1
Language：English Publishing type：Research paper (scientific journal) Publisher：Journal of Cardiac Failure
Background: We investigated the clinical significance of the derivative of reactive oxygen metabolites (DROM), a new marker of reactive oxygen species (ROS), in patients with heart failure (HF) with reduced left ventricular ejection fraction (LVEF) (HFrEF). Methods and Results: Serum DROM concentrations were measured in 201 consecutive patients with HFrEF (EF < 50%) in stable condition. DROM values were significantly higher in patients with HFrEF than in risk-matched patients without HF (P < 0.01). They also correlated significantly with high-sensitivity C-reactive protein and B-type natriuretic peptide. Kaplan-Meier analysis demonstrated significantly higher probabilities of HF-related events in the high-DROM group than in the low-DROM group (log-rank test, P < 0.01). Multivariable Cox hazard analysis revealed that DROM were independent and significant predictors of cardiovascular events. In a subgroup analysis, DROM levels were also measured at the aortic root and coronary sinus in 49 patients. The transcardiac gradient of DROM values was significantly higher in patients with HFrEF than in patients without HF (P = 0.04), indicating an association between DROM production in the coronary circulation and HFrEF development. Changes in DROM following optimal therapy were significantly associated with LVEF improvement (r = 0.34, P = 0.04). Conclusions: The higher levels of DROM and their association with cardiovascular events suggest the clinical benefit of DROM measurements in the risk stratification of patients with HFrEF.
-
To what extent can the effect of antithrombotic therapy be evaluated? Reviewed
Heart view 25 ( 1 ) 26 - 31 2021.1
Authorship：Lead author, Corresponding author Language：Japanese Publishing type：Research paper (scientific journal)
-
Misumi I., Sato K., Nagano M., Yamada Y., Urata J., Kaikita K., Tsujita K.
Journal of Echocardiography 19 266 - 268 2021
Language：English Publishing type：Research paper (scientific journal) Publisher：Journal of Echocardiography
-
Left ventricular apical thrombus mimicking hypertrabeculation.
Misumi I, Sato K, Nagano M, Obata M, Urata J, Usuku H, Kaikita K, Tsujita K.
Intern Med 60 2245 - 2250 2021
Language：English Publishing type：Research paper (scientific journal)
-
Morikawa K., Takashio S., Sato R., Yamamoto E., Kaikita K., Tsujita K., Komohara Y.
Internal Medicine 59 ( 24 ) 3171 - 3175 2020.12
Language：English Publishing type：Research paper (scientific journal) Publisher：Internal Medicine
We herein report the histological findings of a patient who had progressed to persistent cardiac arrest for 25 days due to lymphocytic fulminant myocarditis despite mechanical circulatory support (MCS). There were few residual cardiomyocytes, and extensive replacement fibrosis was present. Therefore, improvement of the cardiac function for this patient was considered improbable. Further research is warranted to improve predictions for the recovery of the cardiac function and optimize MCS strategies for patients with fulminant myocarditis.
-
Association of short term exposure to Asian dust with increased blood pressure Reviewed
Ishii M., Seki T., Sakamoto K., Kaikita K., Miyamoto Y., Tsujita K., Masuda I., Kawakami K.
Scientific Reports 10 ( 1 ) 17630 2020.12
Language：English Publishing type：Research paper (scientific journal) Publisher：Scientific Reports
Air pollution causes hypertension, cardiovascular disease, and mortality. Asian dust (AD) reportedly induces asthma or acute myocardial infarction along with air pollution, but its impact on blood pressure (BP) is unknown. We investigated the association between short-term AD exposure and BP fluctuations in 300,952 individuals whose BP was measured during April 2005–March 2015 and divided them into AD and non-AD groups based on visitation for AD-related events. AD’s occurrence, air pollutants’ concentration (suspended particulate matter, SO , NO , photochemical oxidants), and meteorological variables (mean ambient temperature, relative humidity) were obtained from a monitoring station; AD events correlated with decreased visibility (< 10 km). We observed 61 AD days, with 3897 participants undergoing medical check-ups. Short-term AD exposure at lag day-0 was significantly associated with higher systolic BP (SBP), diastolic BP (DBP), and pulse rate (PR) risk (β = 1.85, 95% confidence interval (CI) 1.35–2.35 for SBP, β = 2.24, 95% CI 1.88–2.61 for DBP, β = 0.52, 95% CI 0.14–0.91 for PR) using multi-pollutant model. Population-attributable fractions exposed to AD were 11.5% for those with elevated SBP (SBP ≥ 120 mmHg) and 23.7% for those with hypertension (SBP ≥ 140 mmHg or DBP ≥ 90 mmHg). This study showed a strong association between short-term AD exposure and increased SBP and DBP. 2 2
-
Questionnaire in patients with aborted sudden cardiac death due to coronary spasm in Japan Reviewed
Sueda S., Shinohara T., Takahashi N., Shite J., Shoji T., Akao M., Kijima Y., Masuyama T., Miyaji T., Yamamoto K., Iwasaki Y., Yoshida R., Nakamura S., Ogino Y., Kimura K., Sasai M., Suzuki H., Wakatsuki T., Asajima H., Teragawa H., Ishikawa T., Kitamura K., Oda T., Nakayama T., Kobayashi Y., Sunada D., Yamaki M., Nishizaki F., Tomita Y., Usuda K., Fujinaga H., Kuramitsu S., Andou K., Kiyooka T., Kadota K., Ishii Y., Ohtani H., Maekawa Y., Taguchi E., Nakao K., Kobayashi N., Seino Y., Nakagawa H., Saito Y., Komuro I., Sasaki Y., Ikeda S., Yamaguchi O., Kakutani A., Imanaka T., Ishihara M., Ishii M., Kaikita K., Tsujita K.
Heart and Vessels 35 ( 12 ) 1640 - 1649 2020.12
Language：English Publishing type：Research paper (scientific journal) Publisher：Heart and Vessels
Objectives: We investigated the medical or mechanical therapy, and the present knowledge of Japanese cardiologists about aborted sudden cardiac death (ASCD) due to coronary spasm. Methods: A questionnaire was developed regarding the number of cases of ASCD, implantable cardioverter–defibrillator (ICD), and medical therapy in ASCD patients due to coronary spasm. The questionnaire was sent to the Japanese general institutions at random in 204 cardiology hospitals. Results: The completed surveys were returned from 34 hospitals, giving a response rate of 16.7%. All SCD during the 5 years was observed in 5726 patients. SCD possibly due to coronary spasm was found in 808 patients (14.0%) and ASCD due to coronary spasm was observed in 169 patients (20.9%). In 169 patients with ASCD due to coronary spasm, one or two coronary vasodilators was administered in two-thirds of patients [113 patients (66.9%)], while more than 3 coronary vasodilators were found in 56 patients (33.1%). ICD was implanted in 117 patients with ASCD due to coronary spasm among these periods including 35 cases with subcutaneous ICD. Majority of cause of ASCD was ventricular fibrillation, whereas pulseless electrical activity was observed in 18 patients and complete atrioventricular block was recognized in 7 patients. Mean coronary vasodilator number in ASCD patients with ICD was significantly lower than that in those without ICD (2.1 ± 0.9 vs. 2.6 ± 1.0, p < 0.001). Although 16 institutions thought that the spasm provocation tests under the medications had some clinical usefulness of suppressing the next fatal arrhythmias, spasm provocation tests under the medication were performed in just 4 institutions. Conclusions: In the real world, there was no fundamental strategy for patients with ASCD due to coronary spasm. Each institution has each strategy for these patients. Cardiologists should have the same strategy and the same knowledge about ASCD patients due to coronary spasm in the future.